Pulse Biosciences reports Q4 2022 net loss of $9.2M, no revenue; shifts focus to atrial fibrillation

PULSE BIOSCIENCES, INC.

Q4 2022 GAAP net loss of $9.2M vs $15.4M in Q4 2021; non-GAAP net loss $8.1M.
No revenue in Q4 2022; full-year 2022 revenue $0.7M from discontinued dermatology.
Cash, cash equivalents and investments $61.1M at Dec 31, 2022; cash burn reduced to $8.0M in Q4.
Company focuses on nsPFA cardiac ablation for atrial fibrillation; FDA pre-submission for clamp planned in Q2 2023.
Appointed Manmeet S. Soni as Lead Independent Director with $80,000 annual fee.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Manmeet S. Soni

Lead Independent Director

PLSE · PULSE BIOSCIENCES, INC.

Effective: 2023-03-28
Filed: March 30, 2023, 7:59 PM ET

On March 28, 2023, the Company's Board of Directors appointed Manmeet S. Soni to the newly created position of Lead Independent Director of the Board of Directors.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PULSE BIOSCIENCES, INC. reported financial results for the fourth quarter and full year ended December 31, 2022.

Period: the fourth quarter and full year ended December 31, 2022
Result: reported results

Exact text from the filing

Pulse Biosciences, Inc. (the “Company”) announced its financial and operational results for the fiscal quarter and full year ended December 31, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Manmeet S. Soni was appointed as Lead Independent Director at PULSE BIOSCIENCES, INC..

Action: appointed
Role: Lead Independent Director

Exact text from the filing

On March 28, 2023, the Company's Board of Directors appointed Manmeet S. Soni to the newly created position of Lead Independent Director of the Board of Directors.

View on SEC.gov

Browse all earnings releases →

PULSE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-008625

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.